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Abstract
Background: To describe the scoring methodology and MRI assessments used to evaluate the cross-sectional
features observed in cases and controls, to define change over time for different MRI features, and to report the
extent of changes over a 24-month period in the Foundation for National Institutes of Health Osteoarthritis
Biomarkers Consortium study nested within the larger Osteoarthritis Initiative (OAI) Study.
Methods: We conducted a nested case–control study. Cases (n = 406) were knees having both radiographic and
pain progression. Controls (n = 194) were knee osteoarthritis subjects who did not meet the case definition. Groups
were matched for Kellgren-Lawrence grade and body mass index. MRIs were acquired using 3 T MRI systems and
assessed using the semi-quantitative MOAKS system. MRIs were read at baseline and 24 months for cartilage
damage, bone marrow lesions (BML), osteophytes, meniscal damage and extrusion, and Hoffa- and effusion-synovitis.
We provide the definition and distribution of change in these biomarkers over time.
Results: Seventy-three percent of the cases had subregions with BML worsening (vs. 66 % in controls) (p = 0.102). Little
change in osteophytes was seen over 24 months. Twenty-eight percent of cases and 10 % of controls had worsening
in meniscal scores in at least one subregion (p < 0.001). Seventy-three percent of cases and 53 % of controls had at
least one area with worsening in cartilage surface area (p < 0.001). More cases experienced worsening in Hoffa- and
effusion synovitis than controls (17 % vs. 6 % (p < 0.001); 41 % vs. 18 % (p < 0.001), respectively).
Conclusions: A wide range of MRI-detected structural pathologies was present in the FNIH cohort. More severe
changes, especially for BMLs, cartilage and meniscal damage, were detected primarily among the case group
suggesting that early changes in multiple structural domains are associated with radiographic worsening and
symptomatic progression.
Keywords: Osteoarthritis, MRI, Progression, Scoring, Biomarkers
* Correspondence: froemer@bu.edu; frank.roemer@uk-erlangen.de
1Quantitative Imaging Center, Department of Radiology, Boston University
School of Medicine, FGH Building, 3rd floor, 820 Harrison Avenue, Boston,
MA 02118, USA
2Department of Radiology, University of Erlangen-Nuremberg, Erlangen,
Germany
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Roemer et al. BMC Musculoskeletal Disorders  (2016) 17:466 
DOI 10.1186/s12891-016-1310-6
Background
Knee osteoarthritis (OA) is a major public health con-
cern with current treatment focusing on controlling
symptoms since there are no interventions that have yet
been approved for modifying the course of the disease
or improving structural alterations in joint tissues [1].
The Foundation for the National Institutes of Health
(FNIH) sample was selected for a nested case–control
study designed to evaluate the predictive validity of a
broad spectrum of imaging and biochemical markers of
disease progression in knee OA derived from the Osteo-
arthritis Initiative (OAI) public data base, an ongoing
multi-center prospective observational cohort study of
knee OA [2]. A biomarker that exhibits change over the
near-term and is associated with longer-term clinically
important outcomes would have potential as a marker of
treatment efficacy [2].
While radiography depicts structural bony tissue
changes only in advanced stages of OA, magnetic reson-
ance imaging (MRI) is able to visualize all involved joint
tissues, even in the earliest stages of disease, in which ra-
diographs are normal [3, 4]. Recent data suggest that
non-cartilaginous tissue changes in particular play an
important role in the onset and progression of osteo-
arthritis [5, 6].
Using multivariable logistic regression models to
examine associations between structural MRI markers
and progression of radiographic and pain outcomes, we
showed recently that all baseline structural joint features
with the exception of effusion-synovitis and meniscal
morphology, were able to predict 48 month case status
and that for all joint features evaluated including size of
bone marrow lesions, cartilage thickness and surface
area, effusion-synovitis, meniscus morphology and -ex-
trusion, osteophyte size, and Hoffa-synovitis, change
over 24 months was associated with progression of dis-
ease [7]. However, definitions of change using complex
scoring systems are challenging and need to be defined
carefully prior to engaging in detailed analyses focused
on outcomes and prediction models. As currently only
sparse data are available on reliability and definitions of
change in semi-quantitatively assessed MRI studies, we
believe that a detailed description will be helpful to in-
vestigators focusing on samples at risk for progression;
these data were not covered in the recent publication
[7].
Thus, the aims of our study were to describe the scor-
ing methodology and MRI assessments used to evaluate
the cross-sectional features observed in cases and con-
trols, to define change over time for different MRI fea-
tures and to report the extent of changes over a 24-
month period, which may serve as a potential reference
for future studies focusing on MRI features and progres-
sion over similar observational periods.
Methods
Study design
The Osteoarthritis Initiative (OAI) is an ongoing multi-
center prospective observational cohort study of knee
OA (http://www.oai.ucsf.edu/) that enrolled 4796 partic-
ipants aged 45–79 years at four clinical centers. Clinical
data, MRI scans, radiographs and serum and urine speci-
mens were obtained at baseline, 12, 24, 36, and
48 months (M) follow-up [8]. Eligible participants for
the present study were those with at least one knee with
a Kellgren-Lawrence grade (KLG) of 1–3 at baseline.
Criteria for case–control selection
Radiographic progression was defined by a decrease in
minimal joint space width of ≥0.7 mm in loss in the
medial tibio-femoral compartment from baseline to 24,
36 or 48 M.
Knee pain was assessed using the Western Ontario
McMasters (WOMAC) pain subscale. Symptomatic pro-
gression was defined as a persistent increase of ≥9 points
on a 0–100 normalized score from baseline to 24, 36, 48
or 60 months. This difference has been documented to
be clinically relevant [9].
For the nested case–control study, a predetermined
number of index knees was selected in the following
outcome groups for measurement of imaging bio-
markers [6]: 1) case knees had both radiographic and
pain progression; control knees did not have this com-
bination, and included 2) knees with radiographic but
not pain progression, 3) knees with pain but not radio-
graphic progression, and 4) knees with neither radio-
graphic nor pain progression. The sample size for cases
and these three control groups was 194, 103, 103 and
200 knees, respectively. For the purposes of this analysis
we compared 194 cases vs. 406 controls.
MRI acquisition and assessment
MRIs of both knees were acquired using 3 T systems
(Siemens Trio) at the 4 OAI clinical sites. A dedicated
quadrature transmit/receive knee coil was used and the
sequence protocol included a coronal intermediate-
weighted 2-dimensional turbo spin echo sequence, a sa-
gittal 3-dimensional dual-echo steady-state sequence,
and a sagittal intermediate-weighted fat-suppressed
turbo spin-echo sequence [10].
Two musculoskeletal radiologists with 13 (FWR) and 15
(AG) years’ experience of semi-quantitative assessment of
knee OA, blinded to clinical data and case–control status,
read the baseline and 24 month MRIs according to a vali-
dated scoring system [11], and with knowledge of the
chronological order of the scans. The following joint struc-
tures were assessed: cartilage morphology, osteophytes,
subchondral bone marrow lesions (BMLs), meniscal
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structural damage and meniscal extrusion, Hoffa-synovitis
and effusion-synovitis.
In addition, within-grade changes were coded that ful-
fill the definition of a definite visual change but do not
fulfill the definition of a full grade change on the ordinal
scales applied [12].
Reliability
One experienced musculoskeletal radiologist (FWR) re-
evaluated 20 randomly selected MRIs in random order
after a 4 week interval to assess intra-reader reliability.
Inter-observer reliability between the two readers was
determined using the same 20 cases.
Definition of change over time
BMLs
Change in overall number of subregions affected by any
BML was defined as the difference between the number
of subregions affected by any BML at 24 months (size >
0) and the number of subregions affected by any BML at
baseline. This was further categorized into improvement,
no change, and worsening in one subregion and worsen-
ing in two or more subregions. An example of incident
BML at follow-up is shown in Fig. 1.
We also determined the number of subregions with
worsening, and the number of subregions with improve-
ment. In both instances we took into account within-
grade changes in BML size. We further classified these
measures into any subregions with worsening vs. no sub-
regions with worsening and any subregions with im-
provement vs. no subregions with improvement.
To determine maximum change in BML size score, we
first evaluated change in size score in each of the 14 ar-
ticular subregions between baseline and 24 months.
Change in size score in each subregion could range from
a maximal improvement by three to a maximal
worsening by three. The second step was to create an
overall change in size score that was defined as the max-
imum change in size score across the 14 articular subre-
gions. It was categorized into improvement, no change,
worsening within grade, worsening by 1 grade, and
worsening by two or more grades. Based on distribu-
tional quantities the final grouping included: worsening
by <2 grades (comprised of improvement, within grade
worsening and worsening in at most one grade in size
score) vs. worsening by two or more grades.
Osteophytes
The change in number of locations affected by any
osteophyte was defined as the difference between the
number of locations affected by any osteophyte at
24 months (Grade > 0) and the number of locations af-
fected by any osteophyte at baseline. This change was
classified as no change, worsening in one location, and
worsening by two or more locations and then further
classified into no change vs. any worsening. To
determine maximum worsening in osteophyte score, we
evaluated change in score in each of the 12 locations be-
tween baseline and 24 months. Maximum worsening in
score was defined as the greatest amount of worsening
among the 12 locations. Maximum worsening in score
was initially classified as no change, worsening one
grade, and worsening by two or more grades. Based on
the distribution, the final categorization included no
worsening vs. any worsening.
Meniscus
We assessed whether there was worsening in meniscal
morphology from baseline to 24 months in each of the
six meniscal subregions. We defined worsening as an in-
crease in grade in at least one subregion. Figure 2 shows
an example of increase in meniscal extrusion over time.
Fig. 1 Incident BML and meniscal tear. a Baseline sagittal intermediate-weighted fat suppresed image shows normal cartilage coverage of the
medial femur and tibia and no meniscal damage. There is a definite osteopyhte at the posterior femur (arrow). b Follow-up image shows incident
BML at the anterior medial tibia (short, large arrows) and an incident vertical meniscal tear at the posterior horn of the medial meniscus (arrow-
head). In addition there is a small loose body posterior to the meniscus (long, thin arrow)
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We further categorized worsening in meniscal morph-
ology into number of compartments with worsening
(range 0–6) and whether any of the compartments had
worsening (yes/no). We assessed changes in meniscal ex-
trusion separately in the medial and lateral compart-
ments. We categorized change in extrusion as
improvement, no change, and worsening. We further
dichotomized change in extrusion as no worsening vs.
any worsening.
Cartilage
MOAKS uses a two-digit score for cartilage assessment
that incorporates both area size per subregion and per-
centage of subregion affected by full thickness cartilage









95 % confidence interval
Lower Upper Lower Upper
Intra-observer reliability Inter-observer reliability
Cartilage area involvement (0–3) Whole knee 0.87 0.054 0.76 0.97 0.89 0.053 0.78 0.99
Medial TFJ 0.84 0.092 0.66 1.00 0.87 0.090 0.69 1.00
Lateral TFJ 0.89 0.092 0.71 1.00 0.96 0.093 0.78 1.00
PFJ 0.86 0.094 0.68 1.00 0.82 0.094 0.64 1.00
Cartilage % of subregion
affected by full thickness
damage (0–3)
Whole knee 0.78 0.056 0.67 0.89 0.86 0.055 0.75 0.96
Medial TFJ 0.73 0.091 0.56 0.91 0.84 0.095 0.65 1.00
Lateral TFJ 0.73 0.096 0.54 0.92 0.79 0.093 0.61 0.97
PFJ 0.85 0.101 0.65 1.00 0.92 0.100 0.73 1.00
BML size (0–3) Whole knee 0.87 0.050 0.77 0.97 0.90 0.050 0.80 1.00
Medial TFJ 0.84 0.081 0.68 1.00 0.90 0.082 0.74 1.00
Lateral TFJ 0.90 0.087 0.73 1.00 0.90 0.086 0.73 1.00
PFJ 0.87 0.093 0.69 1.00 0.89 0.092 0.71 1.00
Meniscus Morphology
(0–8)
Whole knee 0.97 0.085 0.81 1.00 0.99 0.085 0.82 1.00
Medial TFJ 0.97 0.112 0.74 1.00 1.00 0.120 0.76 1.00
Lateral TFJ 0.97 0.121 0.73 1.00 0.97 0.121 0.73 1.00
Meniscus Extrusiona
(0–3)
Medial 0.83 0.226 0.38 1.00 0.58 0.208 0.17 0.99
Lateral 0.88 0.228 0.44 1.00 0.76 0.222 0.32 1.00
Hoffa-Synovitis (0–3) 0.68 0.157 0.38 0.99 0.68 0.157 0.38 0.99
Effusion-Synovitis (0–3) 0.95 0.174 0.61 1.00 0.91 0.171 0.57 1.00
aSimple kappa for meniscal extrusion: dichotomized into 0 and 1–3 (>2 mm)
Fig. 2 Progression of meniscal damage and incident cartilage loss over 24 months. a Baseline coronal intermediate-weighted image shows
horizontal-oblique tear of the body of the medial meniscus (arrow). There is no apparent cartilage damage at the tibia or femur at the medial
compartment. b Follow-up image obtained 24 months later shows marked incident meniscal extrusion (black-filled arrow) and newly developed
cartilage loss at the central portion of the medial tibia (white-filled arrow)
Roemer et al. BMC Musculoskeletal Disorders  (2016) 17:466 Page 4 of 17
loss. In this analysis separate scores for cartilage thick-
ness and surface area were considered. The number of
subregions with worsening (i.e., a higher score at
24 months vs. baseline) was defined separately for sur-
face area and thickness. Change over time for surface
area was computed in two ways: including within-grade
changes and excluding-within grade changes. Within
grade scoring for cartilage refers to within grade change
in area or thickness. For both thickness and surface area,
worsening was grouped into 4-levels: 0, 1, 2, or 3 or
more areas with worsening.
Hoffa-synovitis and effusion-synovitis
As MRI markers of inflammation so-called effusion- and
Hoffa-synovitis are evaluated. Fluid sensitive sequences
as applied in the OAI are capable of delineating intraar-
ticular joint fluid but a distinction between true joint ef-
fusion and synovial thickening is not possible as both
are visualized as hyperintense signal within the joint cav-
ity. For this reason the term effusion-synovitis has been
introduced, which is scored based on the distension of
the joint capsule. Hoffa-synovitis is a term used for
signal changes in Hoffa’s fat pad that are commonly used
as a surrogate for synovitis on non-contrast enhanced
MRI. Effusion-synovitis is scored from 0 to 3 according
to the distention of the joint capsule as 1 = small, 2 =
moderate and 3 = large. Hoffa-synovitis is scored based
on the amount of hyperintensity signal in Hoffa’s fat pad
on sagittal fat suppressed intermediate-weighted se-
quences as 1 = mild, 2 =moderate and 3 = severe.
Twenty-four month changes in both, Hoffa-synovitis
and effusion-synovitis were categorized as improvement,
no change, or worsening.
Analytic approach
Descriptive statistics were used to report frequencies
for the different features and parameters for baseline
and change over time. Logistic regression was used to
identify factors associated with statistically significant
differences between cases and controls. For some fea-
tures raw distributions were grouped into categories as
described above. In these instances descriptive statis-
tics are presented for both raw and categorical versions
of features, and regression was used only for the
Table 2 Baseline frequencies of semi-quantitative MRI biomarkers – BMLs
MRI feature Biomarker Overall
n (%)
Controls Cases p-value
BML Number of subregions
affected by any BML
0 66 (11 %) 55 (13.5 %) 11 (5.7 %)
1 98 (16 %) 76 (18.7 %) 22 (11.3 %)
2 126 (21 %) 88 (21.7 %) 38 (19.6 %)
3 129 (22 %) 88 (21.7 %) 41 (21.1 %)
4 84 (14 %) 52 (12.8 %) 32 (16.5 %)
5 59 (10 %) 27 (6.7 %) 32 (16.5 %)
6 26 (4 %) 14 (3.4 %) 12 (6.2 %)
7 8 (1 %) 5 (1.2 %) 3 (1.5 %)
8 4 (1 %) 1 (0.2 %) 3 (1.5 %)
Number of subregions
affected by any BML
<0.001*
0 66 (11 %) 55 (13.5 %) 11 (5.7 %)
1 98 (16 %) 76 (18.7 %) 22 (11.3 %)
2 126 (21 %) 88 (21.7 %) 38 (19.6 %)
3 129 (22 %) 88 (21.7 %) 41 (21.1 %)
4 84 (14 %) 52 (12.8 %) 32 (16.5 %)
5+ 97 (16 %) 47 (11.6 %) 50 (25.8 %)
Max BML score in knee 0.016*
0 66 (11 %) 55 (13.5 %) 11 (5.7 %)
1 223 (37 %) 148 (36.5 %) 75 (38.7 %)
2 202 (34 %) 138 (34.0 %) 64 (33.0 %)
3 109 (18 %) 65 (16.0 %) 44 (22.7 %)
*statistically significant at p < 0.05; p values refer to differences between cases and controls across all grades
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categorical version. Weighted kappa statistics were ap-
plied to determine inter- and intra-observer reliability.
All analyses were conducted in SAS 9.4 (SAS Institute,
Cary NC).
Results
Mean age of the participants was 62 years, 60 % were
women and average BMI was 30 kg/m2 [5]. Cases and
controls were balanced on all covariates, with the ex-
ception of baseline KLG with a higher proportion of
KL3 knees in the case group (44 %) compared to the
controls (33 %). Summarizing the intra- and inter-
observer reliability results, all of the measures showed
at least substantial agreement ranging between 0.68 for
Hoffa-synovitis and 0.97 for medial and lateral menis-
cal morphology. Table 1 gives a detailed overview of
the reliability results.
BMLs
The number of sub-regions affected by any BML ranged
from zero to eight and the maximum BML score per knee
ranged from zero to three. The change in number of subre-
gions affected by any BML ranged from −3 (three fewer
subregions affected at 24 months compared to baseline) to
5 (five more subregions affected at 24 months compared to
baseline). Fourteen percent of subjects showed improve-
ment in number of subregions with BMLs (fewer subre-
gions with BMLs at 24 months as compared to baseline)
and 52 % showed no change based on this definition.
Seventy-three percent of the cases had any subregions with
worsening (vs. 66 % in the control group).
Osteophytes
The number of locations with any osteophytes ranged
from zero to 12. The maximum osteophyte score per
Table 3 Baseline frequencies of semi-quantitative MRI biomarkers – osteophytes
MRI feature Biomarker Overall n (%) Controls Cases p-value
Osteophytes Number of locations affected
by any osteophyte
0 19 (3 %) 15 (3.7 %) 4 (2.1 %)
1 34 (6 %) 30 (7.4 %) 4 (2.1 %)
2 42 (7 %) 36 (8.9 %) 6 (3.1 %)
3 58 (10 %) 43 (10.6 %) 15 (7.7 %)
4 54 (9 %) 39 (9.6 %) 15 (7.7 %)
5 47 (8 %) 38 (9.4 %) 9 (4.6 %)
6 45 (8 %) 28 (6.9 %) 17 (8.8 %)
7 37 (6 %) 23 (5.7 %) 14 (7.2 %)
8 49 (8 %) 26 (6.4 %) 23 (11.9 %)
9 41 (7 %) 26 (6.4 %) 15 (7.7 %)
10 47 (8 %) 30 (7.4 %) 17 (8.8 %)
11 48 (8 %) 33 (8.1 %) 15 (7.7 %)
12 79 (13 %) 39 (9.6 %) 40 (20.6 %)
Number of locations affected
by any osteophyte category
<0.001*
0–2 95 (16 %) 81 (20.0 %) 14 (7.2 %)
3–5 159 (27 %) 120 (29.6 %) 39 (20.1 %)
6+ 346 (58 %) 205 (50.5 %) 141 (72.7 %)
Max osteophyte score in knee
0 19 (3 %) 15 (3.7 %) 4 (2.1 %)
1 290 (48 %) 209 (51.5 %) 81 (41.8 %)
2 202 (34 %) 132 (32.5 %) 70 (36.1 %)
3 89 (15 %) 50 (12.3 %) 39 (20.1 %)
Max osteophyte score in knee category 0.011*
0–1 309 (52 %) 224 (55.2 %) 85 (43.8 %)
2 202 (34 %) 132 (32.5 %) 70 (36.1 %)
3 89 (15 %) 50 (12.3 %) 39 (20.1 %)
*statistically significant at p < 0.05; p values refer to differences between cases and controls across all grades
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knee was zero for 3 % of knees, one for 48 %, two for
34 % and three for 15 % of the knees. Overall there was
very little change in osteophytes over 24 months. Nine
percent of the cohort had at least one location that
worsened in osteophyte score over 24 months. Across all
locations, the maximum amount of worsening was 2
grades (i.e., zero to two or one to three) and 83 % had
no change in any location.
Meniscus
Thirty percent of the knees had any meniscal tear and
28 % showed meniscal substance loss (i.e. maceration).
The number of regions with meniscal morphology wors-
ening ranged from zero to five, with 16 % of subjects
having worsening in at least one subregion. Fourteen
percent showed an increase in medial meniscal extrusion
while only one knee had an increase in lateral extrusion.
Cartilage
The number of subregions with worsening in cartilage
surface area, including within-grade changes, ranged
from zero to eight with 59 % of subjects having at least
one area with worsening in surface area. The number of
subregions with cartilage thickness score > 0 ranged
from zero to seven. Across the entire knee, the number
of areas with worsening in cartilage thickness ranged
from zero to six with 42 % of subjects having at least
one area with worsening in thickness.
Hoffa-synovitis
MOAKS Hoffa-synovitis score ranged from zero to
seven and with 24 month change ranging from −2 to 2.
While only 10 % of subjects experienced worsening,
more cases experienced worsening than controls (17 %
vs. 6 %).
Effusion-synovitis
MOAKS effusion-synovitis score ranged from zero to
three with 24 month changes ranging from −2 to 2.
Forty-one percent of cases worsened compared to 18 %
of controls.
Apart from meniscal damage and effusion-synovitis,
baseline frequencies of all measures showed statistically
significant differences for cases vs. controls. For change
parameters, maximum worsening of BML score,
24 months change in osteophytes and meniscal damage
and extrusion, all cartilage measures, and Hoffa- and
effusion-synovitis showed significant differences between
cases and controls.
Tables 2, 3 and 4 present the baseline frequencies of
BMLs, osteophytes and the menisci including the group-
ing of the different scores into broader summary cat-
egories, while Tables 5 and 6 show in detail the
frequencies for cartilage, Hoffa- and effusion-synovitis.
The change observations for the different features are
presented in detail in Tables 7, 8, 9 and 10.








grade in all meniscal
subregions
0.345
0 (normal or signal
only, grades 0 and 1)
253 (42 %) 178 (43.8 %) 75 (38.7 %)
1 (any tear, grades 2–5) 179 (30 %) 114 (28.1 %) 65 (33.5 %)




Grade 0: < 2 mm 202 (34 %) 151 (37.4 %) 51 (26.3 %)
Grade 1: 2–2.9 mm 176 (29 %) 119 (29.5 %) 57 (29.4 %)
Grade 2: 3–4.9 mm 164 (27 %) 106 (26.2 %) 58 (29.9 %)
Grade 3: > 5 mm 56 (9 %) 28 (6.9 %) 28 (14.4 %)
Meniscal Extrusion:
lateral
Grade 0: < 2 mm 577 (96 %) 387 (95.3 %) 190 (97.9 %)
Grade 1: 2–2.9 mm 7 (1 %) 5 (1.2 %) 2 (1.0 %)
Grade 2: 3–4.9 mm 15 (3 %) 13 (3.2 %) 2 (1.0 %)
Grade 3: > 5 mm 1 (0 %) 1 (0.2 %) 0 (0.0 %)
*statistically significant at p < 0.05; p values refer to differences between cases and controls across all grades
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Table 5 Baseline frequencies of semi-quantitative MRI biomarkers – cartilage
MRI feature Biomarker Overall n (%) Controls Cases p-value
Cartilage MOAKS Cartilage Morphology-Thickness-
Max score across entire knee
0.012*
0 150 (25 %) 118 (29.1 %) 32 (16.5 %)
1 127 (21 %) 83 (20.4 %) 44 (22.7 %)
2 290 (48 %) 184 (45.3 %) 106 (54.6 %)
3 33 (6 %) 21 (5.2 %) 12 (6.2 %)
MOAKS Cartilage Morphology-
Thickness-Number of subregions
with score > 0 across entire knee
0 150 (25 %) 118 (29.1 %) 32 (16.5 %)
1 169 (28 %) 112 (27.6 %) 57 (29.4 %)
2 123 (21 %) 82 (20.2 %) 41 (21.1 %)
3 78 (13 %) 46 (11.3 %) 32 (16.5 %)
4 54 (9 %) 34 (8.4 %) 20 (10.3 %)
5 19 (3 %) 11 (2.7 %) 8 (4.1 %)
6 4 (1 %) 2 (0.5 %) 2 (1.0 %)
7 3 (1 %) 1 (0.2 %) 2 (1.0 %)
MOAKS Cartilage Morphology-
Thickness-Number of subregions
with score > 0 across entire knee category
0.002*
0 150 (25 %) 118 (29.1 %) 32 (16.5 %)
1,2 292 (49 %) 194 (47.8 %) 98 (50.5 %)
3+ 158 (26 %) 94 (23.2 %) 64 (33.0 %)
MOAKS Cartilage Morphology-
Surface Area - Max score across entire knee
0 12 (2 %) 12 (3.0 %) 0 (0.0 %)
1 28 (5 %) 22 (5.4 %) 6 (3.1 %)
2 430 (72 %) 297 (73.2 %) 133 (68.6 %)
3 130 (22 %) 75 (18.5 %) 55 (28.4 %)
MOAKS Cartilage Morphology-
Surface Area - Max score across
entire knee Category
0.004*
0–1 40 (7 %) 34 (8.4 %) 6 (3.1 %)
2 430 (72 %) 297 (73.2 %) 133 (68.6 %)














Table 5 Baseline frequencies of semi-quantitative MRI biomarkers – cartilage (Continued)
MOAKS Cartilage Morphology-
Surface Area-Number of
subregions with score > 0 across entire knee
0 12 (2 %) 12 (3.0 %) 0 (0.0 %)
1 33 (6 %) 28 (6.9 %) 5 (2.6 %)
2 50 (8 %) 34 (8.4 %) 16 (8.2 %)
3 78 (13 %) 59 (14.5 %) 19 (9.8 %)
4 102 (17 %) 81 (20.0 %) 21 (10.8 %)
5 111 (19 %) 69 (17.0 %) 42 (21.6 %)
6 88 (15 %) 54 (13.3 %) 34 (17.5 %)
7 50 (8 %) 30 (7.4 %) 20 (10.3 %)
8 36 (6 %) 18 (4.4 %) 18 (9.3 %)
9 23 (4 %) 12 (3.0 %) 11 (5.7 %)
10 13 (2 %) 7 (1.7 %) 6 (3.1 %)
11 2 (0 %) 1 (0.2 %) 1 (0.5 %)
12 1 (0 %) 1 (0.2 %) 0 (0.0 %)
13 1 (0 %) 0 (0.0 %) 1 (0.5 %)
MOAKS Cartilage Morphology-
Surface Area - Number of subregions
with score > 0 across entire knee category
<0.001*
0–1 45 (8 %) 40 (9.9 %) 5 (2.6 %)
2–4 230 (38 %) 174 (42.9 %) 56 (28.9 %)
5–7 249 (42 %) 153 (37.7 %) 96 (49.5 %)
8+ 76 (13 %) 39 (9.6 %) 37 (19.1 %)















In this cohort of subjects at risk for OA progression, the
values for several tissue-specific MRI features associated
with progression of disease vary widely and show great
change or fluctuation. The subgroup defined as cases
based on composite progression of structural and clin-
ical features exhibited changes to a greater extent than
the controls on several features. Specifically, we ob-
served greater change in the case group on maximum
change in BMLs, worsening of BMLs in two or more
subregions, worsening of cartilage surface area and
thickness in three or more subregions and worsening of
meniscal damage. Inflammatory markers of disease, i.e.
Hoffa- and effusion-synovitis, also worsened more fre-
quently in the case group compared to the controls em-
phasizing the potential role of inflammation in disease
progression [13–15]. Overall little change was observed
for osteophytes reflecting the generally slow course of
the disease.
Focusing on the identical dataset, we could show using
a multivariable approach that 24-month change in cartil-
age thickness, cartilage surface area, synovitis-effusion,
Hoffa-synovitis, and meniscal morphology were associ-
ated with disease progression independently, suggesting
that they may serve as efficacy biomarkers in clinical tri-
als of disease modifying interventions for knee OA [7].
Definition of change using semi-quantitative approaches
is challenging as there are multiple possible definitions
including subregional or maximum-grade approaches.
To gain additional understanding of frequencies and cat-
egories encountered in this cohort selected on the basis
of progression or serving as controls we performed the
current analysis that may help researchers in the future
to power planned observational studies or clinical trials.
Few studies are available that have focused on longitu-
dinal change of MRI parameters using semi-quantitative
assessment. Most available studies are centered around
baseline predictors of subsequent cartilage loss as the
outcome [16]; only few studies focus on cartilage as a
predictor of worsening BMLs as the outcome [17].
When assessing change using semi-quantitative scoring
in OA, scores are commonly presented as mean values
or summed over a defined anatomical region (commonly
compartment or knee) [18, 19]. For several reasons, such
approaches have drawbacks that need to be considered.
One of the main shortcomings is that sums are challen-
ging to compare. As an example, a sum of six acquired
over six distinct subregions may mean one lesion with a
grade 6 (considered severe) while five other subregions
exhibit no lesion (grade 0); alternatively, it may reflect
grade 1 lesions in all six subregions. More work is
needed on the prognostic implications of having wide-
spread low grade involvement vs. a focal severe lesion. It
appears likely that both play a role with regard to disease
progression [3]. Other approaches to define progression
have been published recently [20].
Part of the study design was sequential reading of
MRIs not blinded to time point but blinded to case or
control status as it has been shown that this approach
increases sensitivity to change [21]. Reading unblinded
to time point also allowed for the application of within-
grade changes, further increasing sensitivity to detect
minor changes [12]. In assessing MRI data semi-
quantitatively, we are advocating the scoring of the num-
ber of subregions or locations involved by pathology,
with further stratification using cut-offs related to sever-
ity of a certain feature. In addition, an approach asses-
sing a maximum change over a pre-defined unit, such as
a knee compartment or the entire joint, adds to the un-
derstanding of the degree of change observed, which
may be lost using a summative approach. Our definition
of controls included both non-progressors and non-
composite progressors including those that either pro-
gressed clinically (but not radiographically) or radio-
graphically (but not clinically). A further subanalysis is
needed to look at differences in changes for these sub-
groups separately.
Conclusions
In summary, a wide range of MRI-detected structural
pathologies was present in the FNIH cohort. More se-
vere changes, especially for BMLs, cartilage and meniscal
damage, were detected primarily among the case group
suggesting that early changes in multiple structural do-
mains are associated with radiographic worsening and
symptomatic progression. Particularly the role of struc-
tural predictors of progression that are potentially amen-
able to therapeutic approaches such as inflammatory
markers of disease (depicted as Hoffa- and effusion
synovitis on MRI) or subchondral bone changes
Table 6 Baseline frequencies of semi-quantitative MRI biomarkers
–hoffa- and effusion-synovitis






0 246 (41 %) 186 (45.8 %) 60 (30.9 %)
1 302 (50 %) 190 (46.8 %) 112 (57.7 %)
2 47 (8 %) 26 (6.4 %) 21 (10.8 %)




0 233 (39 %) 156 (38.4 %) 77 (39.7 %)
1 250 (42 %) 176 (43.3 %) 74 (38.1 %)
2 97 (16 %) 62 (15.3 %) 35 (18.0 %)
3 20 (3 %) 12 (3.0 %) 8 (4.1 %)
*statistically significant at p < 0.05; p values refer to differences between cases
and controls across all grades
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Table 7 Twenty-four month change in semi-quantitative MRI biomarkers – BMLs
MRI feature Biomarker Overall n (%) Controls Cases p-value
BML Change in Number of
subregions affected by any BML (BL to 24 M)
-3 4 (1 %) 3 (0.7 %) 1 (0.5 %)
-2 6 (1 %) 4 (1.0 %) 2 (1.0 %)
-1 71 (12 %) 48 (11.9 %) 23 (11.9 %)
0 309 (52 %) 214 (52.8 %) 95 (49.0 %)
1 154 (26 %) 105 (25.9 %) 49 (25.3 %)
2 43 (7 %) 24 (5.9 %) 19 (9.8 %)
3 9 (2 %) 7 (1.7 %) 2 (1.0 %)
4 2 (0 %) 0 (0.0 %) 2 (1.0 %)
5 1 (0 %) 0 (0.0 %) 1 (0.5 %)
Change in Number of subregions
affected by any BML (BL to 24 M)
0.318
Improvement 81 (14 %) 55 (13.6 %) 26 (13.4 %)
No Change 309 (52 %) 214 (52.8 %) 95 (49.0 %)
Worsen in 1 subregion 154 (26 %) 105 (25.9 %) 49 (25.3 %)
Worsen in 2+ subregions 55 (9 %) 31 (7.7 %) 24 (12.4 %)
Maximum worsening in BML score
of all subregions in knee (BL to 24 M)
0.003*
0 191 (32 %) 138 (34.1 %) 53 (27.3 %)
1 36 (6 %) 24 (5.9 %) 12 (6.2 %)
2 273 (46 %) 192 (47.4 %) 81 (41.8 %)
3 99 (17 %) 51 (12.6 %) 48 (24.7 %)
Number of subregions with any
improvement in BML (including
within grade changes – BL to 24 months)
0 308 (51 %) 219 (53.9 %) 89 (45.9 %)
1 192 (32 %) 132 (32.5 %) 60 (30.9 %)
2 76 (13 %) 42 (10.3 %) 34 (17.5 %)
3 18 (3 %) 11 (2.7 %) 7 (3.6 %)
4 4 (1 %) 2 (0.5 %) 2 (1.0 %)
5 1 (0 %) 0 (0.0 %) 1 (0.5 %)














Table 7 Twenty-four month change in semi-quantitative MRI biomarkers – BMLs (Continued)
Any subregions with improvement
(including within grade changes) in BML
0.065
No 308 (51 %) 219 (53.9 %) 89 (45.9 %)
Yes 292 (49 %) 187 (46.1 %) 105 (54.1 %)
Number of subregions with any worsening
(including within grade changes) in BML
0 191 (32 %) 138 (34.0 %) 53 (27.3 %)
1 194 (32 %) 143 (35.2 %) 51 (26.3 %)
2 128 (21 %) 79 (19.5 %) 49 (25.3 %)
3 53 (9 %) 31 (7.6 %) 22 (11.3 %)
4 23 (4 %) 9 (2.2 %) 14 (7.2 %)
5 10 (2 %) 6 (1.5 %) 4 (2.1 %)
6 1 (0 %) 0 (0.0 %) 1 (0.5 %)
Any subregions with worsening
(including within grade changes) in BML
0.102
No 191 (32 %) 138 (34.0 %) 53 (27.3 %)
Yes 409 (68 %) 268 (66.0 %) 141 (72.7 %)














Table 8 Twenty-four month change in semi-quantitative MRI biomarkers – osteophytes
MRI feature Biomarker Overall n (%) Controls Cases p-value
Osteophytes 24 M Increase in number of
locations affected by any osteophyte
0.386
No 544 (91 %) 371 (91.4 %) 173 (89.2 %)
Yes 56 (9 %) 35 (8.6 %) 21 (10.8 %)
24 M Change in number of
locations affected by any Osteophyte
0.585
No Change 544 (91 %) 371 (91.4 %) 173 (89.2 %)
Worsen in 1 subregion 32 (5 %) 21 (5.2 %) 11 (5.7 %)
Worsen in 2+ subregions 24 (4 %) 14 (3.4 %) 10 (5.2 %)
24 M Max change in osteophyte
score across all locations in knee
0 498 (83 %) 347 (85.5 %) 151 (77.8 %)
1 97 (16 %) 55 (13.5 %) 42 (21.6 %)
2 5 (1 %) 4 (1.0 %) 1 (0.5 %)
24 M Max change in osteophyte
score > =1 across all locations in knee
0.021*
No 498 (83 %) 347 (85.5 %) 151 (77.8 %)
Yes 102 (17 %) 59 (14.5 %) 43 (22.2 %)
*statistically significant at p < 0.05; p values refer to differences between cases and controls across all grades
Table 9 Twenty-four month change in semi-quantitative MRI biomarkers – meniscus
MRI feature Biomarker Overall n (%) Controls Cases p-value
Yes 102 (17 %) 59 (14.5 %) 43 (22.2 %)
Meniscus Meniscal Morphology: 24 Month
Number of regions with worsening
0 505 (84 %) 365 (90.1 %) 140 (72.2 %)
1 67 (11 %) 31 (7.7 %) 36 (18.6 %)
2 25 (4 %) 7 (1.7 %) 18 (9.3 %)
3 1 (0 %) 1 (0.2 %) 0 (0.0 %)
5 1 (0 %) 1 (0.2 %) 0 (0.0 %)
Meniscal Morphology: 24 Month
Any regions with worsening
<0.001
No 505 (84 %) 365 (90.1 %) 140 (72.2 %)
Yes 94 (16 %) 40 (9.9 %) 54 (27.8 %)
Meniscal Extrusion Medial -
24 Month worsening
<0.001
No 512 (86 %) 369 (91.3 %) 143 (74.1 %)
Yes 85 (14 %) 35 (8.7 %) 50 (25.9 %)
Meniscal Extrusion Lateral -
24 Month worsening
No 599 (100 %) 405 (99.8 %) 194 (100.0 %)
Yes 1 (0 %) 1 (0.2 %) 0 (0.0 %)
*statistically significant at p < 0.05; p values refer to differences between cases and controls across all grades
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Table 10 Twenty-four month change in semi-quantitative MRI biomarkers – cartilage
MRI feature Biomarker Overall n (%) Controls Cases p-value
Cartilage MOAKS Cartilage Morphology -
entire knee number of areas
with BL to 24 M worsening in thickness
0 348 (58 %) 266 (65.5 %) 82 (42.3 %)
1 132 (22 %) 83 (20.4 %) 49 (25.3 %)
2 77 (13 %) 39 (9.6 %) 38 (19.6 %)
3 34 (6 %) 13 (3.2 %) 21 (10.8 %)
4 8 (1 %) 5 (1.2 %) 3 (1.5 %)
6 1 (0 %) 0 (0.0 %) 1 (0.5 %)
MOAKS Cartilage Morphology -
entire knee number of areas
with BL to 24 M worsening in thickness
<0.001
No Change 348 (58 %) 266 (65.5 %) 82 (42.3 %)
Worsen in 1 subregion 132 (22 %) 83 (20.4 %) 49 (25.3 %)
Worsen in 2 subregions 77 (13 %) 39 (9.6 %) 38 (19.6 %)
Worsen in 3+ subregions 43 (7 %) 18 (4.4 %) 25 (12.9 %)
MOAKS Cartilage Morphology -
entire knee number of areas
with BL to 24 M worsening in
surface area (include within-grade change)
0 246 (41 %) 193 (47.5 %) 53 (27.3 %)
1 176 (29 %) 122 (30.0 %) 54 (27.8 %)
2 91 (15 %) 52 (12.8 %) 39 (20.1 %)
3 60 (10 %) 31 (7.6 %) 29 (14.9 %)
4 20 (3 %) 6 (1.5 %) 14 (7.2 %)
5 5 (1 %) 2 (0.5 %) 3 (1.5 %)
6 1 (0 %) 0 (0.0 %) 1 (0.5 %)
8 1 (0 %) 0 (0.0 %) 1 (0.5 %)
MOAKS Cartilage Morphology -
entire knee number of areas with
BL to 24 M worsening in surface area
(include within-grade change)
<0.001
No Change 246 (41 %) 193 (47.5 %) 53 (27.3 %)














Table 10 Twenty-four month change in semi-quantitative MRI biomarkers – cartilage (Continued)
Worsen in 2 subregions 91 (15 %) 52 (12.8 %) 39 (20.1 %)
Worsen in 3+ subregions 87 (15 %) 39 (9.6 %) 48 (24.7 %)
MOAKS Cartilage Morphology -
entire knee number of areas with
BL to 24 M worsening in surface area
(exclude within-grade change)
0 382 (64 %) 277 (68.2 %) 105 (54.1 %)
1 128 (21 %) 87 (21.4 %) 41 (21.1 %)
2 56 (9 %) 31 (7.6 %) 25 (12.9 %)
3 28 (5 %) 9 (2.2 %) 19 (9.8 %)
4 3 (1 %) 2 (0.5 %) 1 (0.5 %)
5 2 (0 %) 0 (0.0 %) 2 (1.0 %)
6 1 (0 %) 0 (0.0 %) 1 (0.5 %)
MOAKS Cartilage Morphology -
entire knee number of areas with
BL to 24 M worsening in surface area
(exclude within-grade change)
<0.001
No Change 382 (64 %) 277 (68.2 %) 105 (54.1 %)
Worsen in 1 subregion 128 (21 %) 87 (21.4 %) 41 (21.1 %)
Worsen in 2 subregions 56 (9 %) 31 (7.6 %) 25 (12.9 %)
Worsen in 3+ subregions 34 (6 %) 11 (2.7 %) 23 (11.9 %)














(visualized as BMLs on MRI) should be the focus of
further evaluation. In addition, the complexity of the dif-
ferent semi-quantitative scoring systems needs consider-
ation when engaging in analyses focusing on change
over time. Simply summing scores does not seem to be
sufficient and further validation of analyses taking into
account potentially improving features or within-grade
scoring is urgently needed to take full advantage of the
richness of semi-quantitative data that is considered
complementary to more quantitative approaches based
on segmentation of 3D datasets.
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